68 related articles for article (PubMed ID: 23364482)
1. Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients.
Jaksch P; Wiedemann D; Kocher A; Muraközy G; Augustin V; Klepetko W
Transplantation; 2013 Mar; 95(5):766-72. PubMed ID: 23364482
[TBL] [Abstract][Full Text] [Related]
2. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
6. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
[TBL] [Abstract][Full Text] [Related]
7. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
8. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
9. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases.
Kremer BE; Reshef R; Misleh JG; Christie JD; Ahya VN; Blumenthal NP; Kotloff RM; Hadjiliadis D; Stadtmauer EA; Schuster SJ; Tsai DE
J Heart Lung Transplant; 2012 Mar; 31(3):296-304. PubMed ID: 22112992
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
14. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
15. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
16. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
Raj R; Frost AE
J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
[TBL] [Abstract][Full Text] [Related]
18. Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients.
Ramirez-Avila L; Garner OB; Cherry JD
Pediatr Transplant; 2014 Sep; 18(6):599-601. PubMed ID: 25041939
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
[TBL] [Abstract][Full Text] [Related]
20. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]